Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.04.01.646686

Integrative Multi-Omics Analysis of Melanoma: Uncovering Pathways Associated with Immunotherapy Outcomes

Abstract

PurposeThe treatment of advanced malignant melanoma with immune checkpoint blockade (ICB) therapies such as anti-CTLA4 and anti-PD1 has been transformative, yet a significant proportion of patients demonstrate intrinsic resistance or develop severe immune-related adverse events (irAEs), complicating treatment strategies. This study aimed to integrate clinical and molecular data using multi-omics factor analysis (MOFA) To better understand the multifaceted interactions governing ICB resistance and irAE development. MethodsMelanoma patient-derived xenograft tumors with transcriptomic and microbiome data were analyzed using the MOFA2 R package. Simulations assessed MOFA2s performance with small sample sizes. Transcriptomic and microbiome data were normalized and analyzed with MOFA2, and gene set enrichment analysis (GSEA) was performed. ResultsMOFA2 demonstrated robust performance with small sample sizes in simulations and accurately recapitulated findings from published data. Analysis identified five latent factors associating the tumor transcriptome, tumor microbiome, or both with differences in tumor subtypes, ICB response, and specific irAEs. GSEA highlighted pathways related to oxidative phosphorylation, DNA replication, and immune responses. ConclusionIntegrative analysis of multi-omics data using MOFA2 provides insights into melanoma biology, uncovering distinct molecular pathways underlying clinical phenotypes. These insights contribute to our understanding of the complex biological mechanisms contributing to differences in melanoma clinical and tumor characteristics and treatment response, offering potential insight towards future development of more personalized and effective diagnostic, prognostic, and therapeutic strategies for patients. Context SummaryThis study aims to integrate multi-omics data, specifically transcriptomic and microbiome datasets, using the MOFA2 computational framework, to understand the complex interplay driving melanoma heterogeneity and response to immune checkpoint blockade (ICB) therapy. The study demonstrates that MOFA2 performs effectively even with small sample sizes, successfully capturing factors that distinguish tumor subtypes, ICB response, and immune-related adverse events (irAEs). It identifies associations between molecular features and clinical outcomes, shedding light on potential mechanisms underlying melanoma pathogenesis and treatment response. By integrating clinical and molecular data, the findings offer insights into the biological underpinnings of melanoma treatment response. Understanding these mechanisms could inform the development of more effective diagnostic, prognostic, and therapeutic strategies for melanoma patients, moving towards personalized oncology approaches.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

MacBeth, M. L., Kaizer, A. M., Wagner, B. D., Couts, K.. 2025-04-07. Integrative Multi-Omics Analysis of Melanoma: Uncovering Pathways Associated with Immunotherapy Outcomes. https://doi.org/10.1101/2025.04.01.646686

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Targeted finetuning enables co-folding models to learn ligand-induced protein conformational states

Advances in protein structure prediction have enabled all-atom protein-ligand co-folding models that predict bound conformations directly from sequence and small-molecule structure. However, these models often fail to generalize to novel binding sites or alternative protein conformational states, limiting their utility for chemical biology and drug discovery. Here we show this limitation reflects training data bias rather than architectural constraints and can be overcome through targeted finetuning. Using ten previously unseen X-ray structures of Werner (WRN) helicase from a drug discovery program, we finetune Boltz-1 to learn both an allosteric binding site and a large conformational change locking the enzyme in an inactive state, while preserving accuracy on the ATP-bound state. The finetuned model generalizes to different chemical series and transfers the conformational logic across RecQ-family helicases in a binding-site sequence-dependent manner. This approach provides a blueprint for adapting foundation models as new structural and mechanistic data emerge, enabling co-folding networks to capture ligand-induced conformational switches and binding poses absent from their training data but central to biological regulation and therapeutic intervention.

bioinformatics↗

Benchmarking single-cell foundation models for aging biology

Single cell foundation models (scFMs) provide representations of cellular states, but their utility across biological questions in aging research remains unclear. We established a benchmark of cellular representations for aging research, evaluating ten general-purpose scFMs, three aging-specific models and conventional methods across five biological questions using more than 2.5 million single cell transcriptomes. Using frozen pretrained representations, Geneformer performed best among scFMs for chronological age prediction and age pseudotime concordance, although 2,000 highly variable genes achieved higher mean performance. Several scFMs captured positive molecular age shifts across three disease contexts, consistent with reported aging-associated changes. SCimilarity performed well for rare cellular state identification across out-of-distribution datasets, exceeding aging specific models and conventional baselines. At the gene level, scGPT showed the highest recovery of reference TF target interactions, including aging-related regulatory hubs. Overall, scFMs supported diverse aging analyses, but performance depended on the biological question, highlighting their utility for rare cellular state identification and regulatory analysis.

bioinformatics↗

CryoMV: Structure-Prior-Guided Modeling and Real-Particle Validation of Continuous Conformational Transitions in Cryo-EM

Continuous protein conformations are essential for understanding fundamental biological processes and supporting drug discovery. Although cryo-EM can resolve individual states at high resolution, recovering continuous heterogeneity from 2D particle images remains challenging. High noise, motion blur, and limited structural priors make it difficult to accurately generate and validate high-resolution continuous conformations using raw particle data. Here, we introduce cryoMV, a framework that integrates structure-prior-guided modeling with real-particle validation for continuous conformational transitions. CryoMV uses reference density maps to establish structural anchors and motion priors, models candidate transition paths between selected conformations, and transfers the learned representation to raw 2D cryo-EM particle images. Each candidate conformation is subsequently evaluated using the estimated particle poses and contrast transfer functions. Supported conformations are reconstructed through raw particle back-projection and assessed using canonical half-maps and Fourier shell correlation. On EMPIAR-10516 and EMPIAR-10345, cryoMV achieves excellent performance in terms of robustness, verifiability, and reconstruction resolution. By incorporating structure-prior modeling and evidence from the raw particles, cryoMV offers an explicit mechanism for assessing whether generated conformations are supported by experimental data and provides a practical approach to reducing model-induced artifacts in continuous cryo-EM heterogeneity analysis.

bioinformatics↗